DYNE THERAPEUTICS, INC.
Last · NASDAQ$15.04-0.26 (-1.70%)close · yahoo · 17h ago
Market cap$2.81B186.7M sh
P/E · TTM-4.6fwd -4.5 · eps -3.30 · loss
Beta1.12vs S&P 500
Div yield0.00%annual · TTM
52w range
$14.00$27.30
Volume2.2Msession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-02
- Operating Cf Burn
- Cash Runway Medium
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Runway Medium — Cash runway ~2.2 years
- Accumulated Deficit High — Accumulated deficit / equity 144%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.89
Est. revenue
0
Press & signals
- GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans